Nootropic peptides occupy a unique space in research compound discussions: smaller, often intranasal-administered molecules with CNS-targeted mechanisms. Semax, Selank, and Dihexa are three of the most frequently discussed. Here is what the published research actually says about each.
Semax
Semax is a synthetic heptapeptide (Met-Glu-His-Phe-Pro-Gly-Pro) developed in Russia, based on a fragment of ACTH (adrenocorticotropic hormone). It is approved in Russia as a nasal spray for various neurological conditions — making it one of the few “nootropic peptides” with any regulatory approval anywhere.
Published Mechanisms
- BDNF upregulation: Multiple rodent studies and some human studies report increased BDNF expression. A 2001 study in Bulletin of Experimental Biology and Medicine showed Semax administration increased BDNF mRNA in rat hippocampus by ~5-fold.
- Neuroprotection: Several rodent studies show protection against ischemic brain injury, potentially via anti-inflammatory and antioxidant mechanisms
- Dopamine system modulation: Published data suggests effects on dopaminergic transmission in the prefrontal cortex
Human Data
More human data exists for Semax than most research peptides due to its Russian clinical history. Studies (mostly Russian-language, some translated) report improvements in memory tests, attention measures, and stroke recovery markers. Sample sizes are generally small. Western peer-reviewed validation is limited.
Selank
Selank is a synthetic heptapeptide (Thr-Lys-Pro-Arg-Pro-Gly-Pro) derived from the endogenous immunomodulatory tetrapeptide tuftsin. Also approved in Russia (as Selank nasal spray) for anxiety and mild cognitive impairment.
Published Mechanisms
- GABA-A modulation: Proposed anxiolytic mechanism involving potentiation of GABA-A receptor function, similar to benzodiazepines but without reported dependency in animal models
- BDNF expression: Like Semax, published data reports BDNF upregulation — suggesting overlapping but distinct mechanisms
- Enkephalin regulation: Published data shows Selank reduces enkephalin degradation, extending endogenous opioid peptide activity
Selank is frequently discussed as an “anxiolytic nootropic” — a compound that may reduce anxiety while maintaining or improving cognitive function, without the sedation or dependence concerns of classical anxiolytics. The published evidence supports this hypothesis in animal models; human data is limited to small Russian trials.
Dihexa
Dihexa (N-hexanoic-Tyr-Ile-(6) aminohexanoic amide) was developed at Washington State University by Dr. Joseph Harding’s lab. It is a hepatocyte growth factor (HGF)/MET signaling system activator.
The Remarkable Rodent Data
The 2013 paper in Neuropsychopharmacology reported that Dihexa was approximately 7 orders of magnitude more potent than BDNF at promoting synaptogenesis in cultured neurons, and improved spatial learning and memory in aged rats with cognitive deficits. These are striking findings that generated significant research interest.
The Human Data Gap
There are no published human clinical trials for Dihexa. Zero. The rodent data is compelling enough to generate genuine scientific interest, but the translational gap means any human use is entirely extrapolated from animal models. This is a higher-uncertainty situation than even most research peptides.
What “Approved in Russia” Actually Means for Evidence Standards
Semax and Selank’s regulatory approval in Russia is often cited as a meaningful credibility signal, and it’s worth being precise about what that actually means. Russian pharmaceutical regulation, historically under the Russian Ministry of Health and its predecessor Soviet-era institutions, has not required the same scale or rigor of Phase 3 randomized controlled trial data that the FDA (or EMA in Europe) requires for approval — a difference in regulatory evidentiary standards that is well documented in comparative pharmaceutical regulation literature, not a judgment specific to these two compounds. This doesn’t mean Russian-approved drugs are ineffective; many bioregulator peptides developed through this system (including Semax, Selank, and the Khavinson-group compounds discussed elsewhere on this site) have genuine decades-long clinical use histories in that regulatory context. But “approved in Russia” is not equivalent to “cleared the same evidentiary bar as an FDA-approved drug,” and readers should calibrate their confidence accordingly rather than treating the two regulatory achievements as interchangeable credibility signals.
Why Independent Western Replication Remains Limited
A structural reason this entire compound class has thinner independent verification than its publication volume might suggest: the bulk of Semax, Selank, and related bioregulator peptide research has been conducted by a relatively concentrated set of Russian research institutions, published substantially in Russian-language journals with limited indexing in Western databases like PubMed, and has not attracted the same volume of independent replication attempts from Western academic labs that better-funded drug classes (like the GLP-1 agonists) have received. This is partly a function of research funding geography and partly a function of language/publication-access barriers rather than necessarily reflecting anything about the underlying biology — but it does mean the practical evidentiary confidence Western researchers can place in this literature is lower than the sheer number of published papers might suggest at first glance.
Frequently Asked Questions
Does Russian regulatory approval mean Semax and Selank meet FDA-equivalent evidence standards?
No — Russian pharmaceutical approval historically has not required the same scale of Phase 3 randomized controlled trial data the FDA requires, a documented difference in regulatory rigor rather than a comment on these specific compounds’ underlying biology.
Why hasn’t more Western research replicated these findings?
Largely funding and publication-access geography — much of the primary literature is Russian-language and less indexed in Western databases, which has limited the volume of independent replication from Western academic labs, distinct from any specific concern about the findings themselves.
Is Dihexa’s complete lack of human trials unusual even for this compound category?
Yes — even relative to Semax and Selank (which have some human data alongside regulatory approval), Dihexa’s evidence base is exclusively preclinical, representing a meaningfully higher translational uncertainty than either of the other two compounds discussed here.
Comparative Evidence Summary
- Semax: Best evidence of the three — rodent + small human trials + regulatory approval in Russia
- Selank: Moderate evidence — rodent + small human trials + regulatory approval in Russia
- Dihexa: Rodent only — striking preclinical data, zero human trials
All three are research-use-only compounds outside of Russia/post-Soviet regulatory frameworks. This content is educational only and does not constitute medical advice.
